Selective activation of anti-CD73 mechanisms in control of primary tumors and metastases

Selective activation of anti-CD73 mechanisms in control of primary tumors and metastases

The emerging role for CD73 in driving cancer growth and metastasis has presented opportunities to develop anti-CD73 monoclonal antibodies (mAbs) in the treatment of human cancers. Blockade of CD73 by antagonistic CD73 mAbs ameliorates tumor growth and metastasis via the inhibition of enzymatic and n...

Full description

Bibliographic Details
Main Authors: Dipti Vijayan, Deborah S. Barkauskas, Kimberley Stannard, Erin Sult, Rebecca Buonpane, Kazuyoshi Takeda, Michele W. L. Teng, Kris Sachsenmeier, Carl Hay, Mark J. Smyth
Format: Article
Language:English
Published: Taylor & Francis Group 2017-05-01
Series:OncoImmunology
Subjects:
adenosine
cd73
combination therapy
immunotherapy
tumor
Online Access:http://dx.doi.org/10.1080/2162402X.2017.1312044

Internet

http://dx.doi.org/10.1080/2162402X.2017.1312044

Similar Items